ICP Biotechnology (ICPbio), a New Zealand based biotechnology company and Wipro BioMed, the healthcare division of Wipro Limited, have entered into an exclusive agreement to market ICPBio's products in India.

Under the terms of the agreement, ICPbio allows Wipro to expand its product portfolio to vaccine manufacturing facility products.

According to Dr Earl Stevens, managing director, ICP Biotechnology Limited, India is becoming a global hub for pharma research and vaccine manufacturing. Serum originating from New Zealand is acknowledged as the "Gold Standard" in managing virus and prion risk as New Zealand is categorized as OIE Category 1 (highest safety), thus NZ sourced products: bovine serums and bovine serum albumins are in great demand worldwide.

Founded in 1988, Wipro BioMed is the healthcare division of Wipro Limited that markets its own brand of instruments for the diagnostics industry under the brand name, LabLife and also markets analytical, life science, laboratory, Diagnostics and Medical instruments of leading technology vendors from USA and Europe.